Cadasil
Conditions
Brief summary
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common form of hereditary cerebral small vessel disease, with no proven disease-modifying treatments. Adrenomedullin, a vasoactive peptide, has angiogenic, vasodilation, anti-inflammatory, and anti-oxidative properties and could have triple sites of action on components of the neuro-glial-vascular unit consisting of vessels, microglia and oligodendrocytes or, more specifically, on the white matter oligovascular unit. The aim of the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients.
Interventions
DRUGAdrenomedullin
Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
Sponsors
National Cerebral and Cardiovascular Center, Japan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who have given written informed consent from the patient or the sponsor to participate in the clinical trial 2. Patients aged between 20 and 90 at the time of obtaining consent 3. Patients diagnosed as CADASIL after confirming NOTCH3 gene mutation by genetic testing 4. Patients with Mini-mental state examination-J score of 10-27 or Trail maiking test score (age ajustment) of average + 1.5 SD (standard deviation) or higher
Exclusion criteria
1. Patients who cannot perform cognitive function tests (deafness, blindness, etc., MMSE-J less than 10 points Severe cognitive impairment, etc.) 2. Patients received reatment with prohibited drugs or prohibited therapy within the past 12 weeks from the time of registration 3. Patients who started to take concomitant restriction drugs or changed dosage of concomitant restriction drugs within the past 4 weeks from the time of registration 4. Patients whose Mini-mental state examination-J with 4 or more points improvements between the time of registration and 4 weeks or more at the time of screening (If patients who take concomitant restriction drugs) 5. Patients with active infections requiring antibiotic treatment at registration 6. Patients with a disability equivalent to modified Rankin Scale 5 at registration 7. Patients with severe consciousness impairment (Japan Coma Scale 100 or more) 8. Patients with severe renal impairment (estimated GFR less than 30 mL / min / 1.73m2) at registration 9. Patients with severe liver damage (transaminase AST (GOT) or ALT (GPT) 100 IU / L or more) at registration 10. Patients diagnosed as having cerebral infarction or intracranial hemorrhage or transient ischemic attack or cerebral aneurysm with high probability of rupture within the last 12 weeks from the time of registration 11. Patients with occlusion or severe stenosis of the intracranial main artery or carotid artery at the time of registration 12. Patients with significant ECG abnormalities (atrioventricular block of 2-3 degrees, extension of QRS interval of 120 ms or more, extension of QTcB of 450 msec or more) at registration, or past histroy of acute coronary syndrome or acute heart failure within the last 12 weeks from the time of registration 13. Patients with systolic blood pressure less than 100 mmHg at registration 14. Patients whose pulse rate is less than 45 beats / minute or 120 beats / minute or more at registration 15. Patients with substance abuse or alcoholism 16. Patients who cannot perform MRI 17. Patients with active solid malignant tumors 18. Patients who do not give consent to contraception from the date of obtaining consent until the end of the safety evaluation period 19. Pregnant, lactating, and possibly pregnant 20. Patient who participated in another trial within 24 weeks before registration 21. Other patients judged by the Investigator or Investigator to be ineligible for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cerebral blood flow change rate evaluated by arterial spin labeling | at 28 days post adrenomedullin administration | Frontal lobe |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean diffusivity change rate of the white matter evaluated by MR diffusion tensor imaging | at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | Whole brain mean and each area |
| Fractional anisotropy change rate of the white matter evaluated by MR diffusion tensor imaging | at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | Whole brain mean and each area |
| Change in times of Trail making test-A/B from baseline evaluation | at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | — |
| Change in scores of Montreal cognitive assessment from baseline evaluation | at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | — |
| Cerebral blood flow change rate evaluated by arterial spin labeling | at 8 hours / 15 days / 90 days / 180 days post adrenomedullin administration | Frontal lobe |
| Occurence of cerebral infarction | at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | — |
| Cerebral blood flow change rate evaluated by single photon emission computed tomography | at 28 days post adrenomedullin administration | Frontal lobe |
| Safety: Serious adverse event | From the initiation of adrenomedullin administration to 28 days post | — |
| Change in scores of Wechsler Adult Intelligence Scale-Fourth edition from baseline evaluation | at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration | — |
Countries
Japan
Outcome results
None listed